Gene Therapy Candidate

(Image: Getty/pinkypills)

Nightstar acquired by Biogen for $800m

By Maggie Lynch

Biogen agrees Nightstar acquisition for $800m to take on its pipeline of AAV treatments for retinal disorders, diversifyingy its pipeline in the rare disease market.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers